Search Results 391-400 of 17893 for Coagulation

1. A Study of Adding AMG 479 to First Line Chemotherapy in Patients with Optimally Debulked Epithelial Ovarian Cancer - Mayo Clinic

   Adequate coagulation parameters within 14 days prior to randomization. International Normalized Ratio (INR) ≤1.5; Activated Prothrombin Time (APTT) ≤ 1.5 x ...

2. A Study of CDX-1127 (Varlilumab) in Patients with Select Solid Tumor Types or Hematologic Cancers - Mayo Clinic

   Is being treated for anti-coagulation (i.e. warfarin) for reasons other than catheter patency. Women who are pregnant or lactating. Prior allogeneic bone ...

3. Executive Health Assessment at Mayo Clinic Healthcare

   • Clotting (coagulation) screen. • Urine microbiology analysis including glucose, pH balance, protein levels, kidney function. • Diabetes screen with ...

4. Study of Exparel Versus Epidural for Pain Control After Thoracotomy - Mayo Clinic

   Allergy to any study medication; coagulation or infectious issues that would preclude epidural catheter placement;; Severe psychological disorders or ...

5. Epicardial Delivery Of XC001 Gene Therapy To Promote Angiogenesis In CAD Patients Undergoing Treatment With CABG - Mayo Clinic

   Participants with uncontrolled coagulation disorder (that cannot be corrected by pharmacotherapy). 3\. Participants with documented, active proliferative ...

6. A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis - Mayo Clinic

   Coagulation: aPTT and prothrombin time (PT) or INR ≤ 1.5 × ULN. Exclusion Criteria: Splenic irradiation within 6 months prior to Screening, or prior ...

7. A Study to Evaluate the Effectiveness and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma - Mayo Clinic

   coagulation 5. History or presence of clinically relevant central nervous system (CNS) pathology 6. Subject with active or history of plasma cell leukemia ...

8. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer - Mayo Clinic

   Renal: Serum Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 60 mL/min as calculated by the Cockroft-Gault method. Coagulation: International ...

9. A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer - Mayo Clinic

   Treatment with Coumadin® or other anti-coagulant therapy (except aspirin) < 4 weeks prior to enrollment; Severe systemic diseases or active uncontrolled ...

10. Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia - Mayo Clinic

    Active disseminated intravascular coagulation (DIC); Active central nervous system (CNS) leukemia; Active, uncontrolled infection; patients with infection ...